FAQ on Soligenix Inc.'s HyBryte Progress in CTCL Treatment
Summary
What is HyBryte and what is its significance in treating CTCL?
HyBryte (TM) is a synthetic hypericin developed by Soligenix Inc. as a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), showing a 75% treatment success rate at 18 weeks and up to 85% improvement in patients treated through 54 weeks, with no serious side effects reported.
Who is Dr. Ellen Kim and what is her role in the HyBryte study?
Dr. Ellen Kim is the Principal Investigator of the ongoing investigator-initiated study on HyBryte and the Director of the Penn Cutaneous Lymphoma Program, who reported the interim data highlighting HyBryte’s efficacy and safety in treating early-stage CTCL.
How does HyBryte compare to traditional CTCL treatments?
HyBryte emerges as a potentially safer, faster-acting alternative to traditional treatments like steroids, chemotherapy, and phototherapy, with its non-mutagenic mechanism and rapid response time, offering renewed hope for patients with this chronic and underserved cancer.
What are the next steps for HyBryte’s development?
Following the successful completion of the second Phase 3 study, Soligenix Inc. will seek regulatory approvals to support potential commercialization of HyBryte worldwide, with ongoing studies like FLASH2 confirmatory trial currently enrolling patients.
Where can I listen to the podcast featuring Dr. Ellen Kim?
The podcast can be viewed at https://ibn.fm/sCfYo, where Dr. Kim discusses the interim data on HyBryte’s progress in treating CTCL.
What other diseases is Soligenix Inc. targeting with its therapies?
Soligenix Inc. is also developing therapies for psoriasis, inflammatory diseases including oral mucositis in head and neck cancer, Behçet’s disease, and has vaccine programs targeting filoviruses and COVID-19, among others.
How can I get more information about Soligenix Inc. and its products?
For further information, visit the company’s website at www.Soligenix.com or check the latest news and updates at https://ibn.fm/SNGX.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 110428